TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05064293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation Arm
Description: Families will be offered a formal assessment to ascertain the primary mental health diagnosis and any co-occurring mental health disorders. After completing the online parent/guardian self-assessment, parents/guardians will meet with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to the navigator for connection to care or study-provided tele-video visits. Navigators will outreach families monthly during the 6-month study period. The navigator will inquire about the child's status and re-evaluate barriers to access. When barriers exist, the navigator will help in facilitating specialty treatment initiation and assess appropriateness of tele-video therapy sessions until ongoing MH services can be arranged. Families/patients reporting that index symptoms have resolved will be offered a 'watchful waiting' approach. Subjects accepting 'watchful waiting' will be outreached quarterly, but not beyond the end of the 6-month follow-up period.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Arm
Description: Families who agree to participate will first be offered a formal assessment in order to ascertain the primary mental health diagnosis and any co-occurring mental health disorders (e.g., substance use). After completing the online parent/guardian self-assessment, parents/guardians will meet for 30 minutes with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to their primary care provider. Control arm participants do not receive navigation.
Study: NCT05637489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PING
Description: Brief survey of goals and preferences
Study: NCT06029673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline 1 MG
Description: Dopamine agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05184101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated Heparin
Description: Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.
Study: NCT05768438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan with upper limb movement
Description: Group A subjects will receive mulligan mobilizations with upper limb movement of the involved side. The patient will be in a sitting position and the therapist will stand beside the patient. The therapist will place one thumb overlapped by the other on one of the selected cervical and then the therapist will push down the spinous process of that specific vertebrae, the pressure will be sustained and the patient will actively abduct his/her arm, assistance will be provided if needed. Initially it will start from 10 repetitions and 1 set which will further progress up to 2 or 3 sets as per patient's tolerance with 60 seconds rest in between each set.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie exercises with neural mobilizations
Description: The subjects of Group B will receive McKenzie exercises. Initially, it will start with retraction exercises. The frequency of exercises will be 10 to 15 repetitions followed by three to four sets with one second hold. On the second or third day, the cervical extension will be added. While in the second week the same set of exercises will be administered with the patient in a sitting position combined with application of over pressure at the end range by therapist. In the third week, extension and retraction exercises will be performed along with traction which will be applied by the therapist. Finally, in the fourth week all retraction and lateral flexion then neck rotation and the last one retraction with neck flexion will be added. Neural mobilizations will be given to patients in group B in supine lying. From proximal to distal, 20 oscillations (1 oscillation/ 1 second)
Study: NCT05897190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine (RBMRNA-405)
Description: Dose A

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine (RBMRNA-405)
Description: Dose A

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac®
Description: Dose B

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac®
Description: Dose B
Study: NCT05076760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEM-288 Intratumoral Injection
Description: Intratumoral injection of MEM-288, conditionally replicative oncolytic adenovirus vector encoding transgenes for human interferon beta (IFNβ) and a recombinant chimeric form of CD40-ligand (MEM40).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEM-288 Intratumoral Injection
Description: Intratumoral injection of MEM-288, conditionally replicative oncolytic adenovirus vector encoding transgenes for human interferon beta (IFNβ) and a recombinant chimeric form of CD40-ligand (MEM40).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: anti-PD1 monoclonal antibody
Study: NCT04384601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Perioperative chemotherapy will be administered according to description in two arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Perioperative chemotherapy will be administered according to description in two arms.
Study: NCT06225024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT
Description: Extracorporeal shock wave therapy (ESWT) is a treatment method based on high-intensity sound waves focusing on the desired body area to provide treatment. ESWT is a safe, non-invasive, alternative treatment for spasticity in patients with stroke, cerebral palsy, and multiple sclerosis and does not cause muscle weakness or adverse effects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BoNT A
Description: BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
Study: NCT05265000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tSpinalStim
Description: Patients will undergo 12-21 sessions of spinal cord stimulation therapy (30 minutes per session, 3 times a week). Up to five round stimulating electrodes will be placed on the skin midline between spinous processes in cervical, thoracic and/or lumbar region, as cathodes and rectangular pads will be placed symmetrically on the skin over the iliac crests as anodes. The stimulator generates pain-free biphasic rectangular waveform with 1 ms width pulses filled with 5-10 kHz (kilohertz) carrier frequency. A range of stimulation intensities from 0-250 mA (milliamps) may be used. We expect that the stimulation intensities needed for therapeutic effect may differ based on individual's body mass index and/or the amount of subcutaneous fat present at the stimulation site.
Study: NCT05491330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)
Description: 2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir 150 mg + Ritonavir 100 mg (test)
Description: 2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)
Description: 2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
Study: NCT03900988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: N-acetyl cysteine will be administered at 100 mg/kg daily as a continuous IV infusion (in 1000ml of 5% dextrose) over 24 hrs and oseltamivir 75 mg bid orally for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
Study: NCT05976763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given PO
Study: NCT06225024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT A
Description: BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
Study: NCT05606536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid Solutions
Description: Locally approved crystalloid solution will be given at the predefined infusion rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid Solutions
Description: Locally approved crystalloid solution will be given at the predefined infusion rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid Solutions
Description: Locally approved crystalloid solution will be given at the predefined infusion rate
Study: NCT05293613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave lithotripsy
Description: shock wave transmited from the device through patient body towards the stone to disintegrate it
Study: NCT05249881

Intervention type: DRUG
Group type: OTHER
Intervention: Semaglutide Pen Injector
Description: All Diabetes mellitus type2 patients fulfilling the inclusion criteria, will receive 0.25mg Semaglutide injection per week and after two weeks dosage will be escalated to 0.5 mg/week for next 10 weeks.
Study: NCT05482178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training plus hypocaloric diet
Description: The exercise program included 3 phases of progressive intervention: 1) Adaptation which included 3-4 days per week at 60% of maximum heart rate, 2) Development phase which included 5 days per week at 75-85% of maximum heart rate and the last one, 3) Maintenance phase which included 5 days per week at 75-90% of maximum heart rate. The control and follow up will be through text message exchanges at least once a week or as many as necessary.~On the other hand, the diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (\>25g per day).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet
Description: The diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (\>25g per day).
Study: NCT05922150

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: LLLT induces cellular biostimulation, speeds up tissue regeneration, enhances wound healing, and reduces pain and swelling through an anti-inflammatory effect. This is because the LLLT increases phagocytic activity, and the number and diameter of lymphatic vessels, decreases the permeability of blood vessels and restores microcapillary function

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: LLLT induces cellular biostimulation, speeds up tissue regeneration, enhances wound healing, and reduces pain and swelling through an anti-inflammatory effect. This is because the LLLT increases phagocytic activity, and the number and diameter of lymphatic vessels, decreases the permeability of blood vessels and restores microcapillary function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozone gel
Description: ozone is effective antimicrobial (viricidal, bactericidal, and fungicidal). Other well-known benefits include immunological modulatory and stimulating effects and anti-inflammatory, biosynthetic, anti-hypoxic, and bioenergeticseffects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozone gel
Description: ozone is effective antimicrobial (viricidal, bactericidal, and fungicidal). Other well-known benefits include immunological modulatory and stimulating effects and anti-inflammatory, biosynthetic, anti-hypoxic, and bioenergeticseffects
Study: NCT05620004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium Bifidum Oral Product
Description: experimental group use Bifidobacterium Bifidum Oral Product and control group without Bifidobacterium Bifidum Oral Product
Study: NCT05946785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylcholine
Description: acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: insulin aspart
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
Study: NCT06462534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Band-Frail Program
Description: Participants will complete 16 weeks of elastic band resistance training and diabetes management education.~Exercise Component:~The elastic band resistance training involves 12 exercises: chair sit-to-stands, seated chest press, seater upper back reverse fly, seated single arm row, seated single arm lateral raise, seated single arm bicep curl, seated single arm triceps extension, seated single leg quadriceps extension, standing hamstring curl, standing leg extension, and seated abdominal crunches.~There will be a one-minute rest between each set and a self-determined rest period between exercises.~Education Component:~A certified Diabetes Educator and registered dietitian will present information to participants covering topics relating to T2D management and nutritional information.
Study: NCT05448313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic intervention
Description: Dyads comprising a Veteran and cohabitating support person will participate in the 16-week VA MOVE! weight loss program delivered by video platform. They will then participate in 6 group sessions focused on weight maintenance skills. Communication skills will be taught throughout the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Veteran-only intervention
Description: Veterans will participate in a 72-week weight management program delivered by video platform. 16 sessions will address weight loss, with 6 additional ones addressing weight loss maintenance.
Study: NCT06389734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual soft tissue release
Description: The manual soft tissue release includes muscle energy techniques and passive stretching, targeting the anterior scalene, upper trapezius, pectoralis major, pectoralis minor, and diaphragm.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial release
Description: The myofascial release includes suboccipital muscle, anterior chest wall myofascial, and anterior neck myofascial.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: The exercise training includes aerobic exercise training by treadmill. The initial intensity is set at 60% to 85% of the average speed measured during the patient's six-minute walk test (6MWT). Intensity adjustments will be made using the Modified Borg Scale (scores ranging from 4 to 7). Training duration is 30 minutes, three times a week for six weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The exercise training includes aerobic exercise training by treadmill. The initial intensity is set at 60% to 85% of the average speed measured during the patient's six-minute walk test (6MWT). Intensity adjustments will be made using the Modified Borg Scale (scores ranging from 4 to 7). Training duration is 30 minutes, three times a week for six weeks.
Study: NCT05694338

Intervention type: OTHER
Intervention: Frailty survey
Description: Frailty survey using the Clinical Risk Analysis Index (RAI-C).
Study: NCT05910034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib+Envafolimab+Docetaxel
Description: This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab+Docetaxel
Description: This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
Study: NCT04656041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX/ nal-IRI
Description: A cycle will be two weeks (14 days) long, with FOLFOX/ nal-IRI administered on days 1-3.~The order of FOLFOX/ nal-IRI administration is as follows:~* 1) Liposomal Irinotecan free base via IV, predetermined dosage per protocol~* 2) Oxaliplatin via IV, predetermined dosage per protocol~* 3) Leucovorin via IV, predetermined dosage per protocol~* 4) 5-Fluorouracil via IV, predetermined dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation Therapy
Description: Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks
Study: NCT06305936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with 100% plant-based diet
Description: The intervention consists of three key components: 1) Educational materials (videos), 2) Participation in a cooking workshop introducing plant-based meals, complete with recipes, and 3) Daily delivery of plant-based dinner meals over a four-week period. The remaining meals during the period are modified by the participant to also adhere to a 100% plant-based composition.
Study: NCT04791566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 1 mg/kg
Description: Dexamethasone 1 mg/kg administered as a single preoperative i.v. infusion over 10-15 min prior to general anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 1 mg/kg
Description: Dexamethasone 1 mg/kg administered as a single preoperative i.v. infusion over 10-15 min prior to general anaesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: 100 mL Physiologic saline administered as a single preoperative i.v., infusion over 10-15 min prior to general anaesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: 100 mL Physiologic saline administered as a single preoperative i.v., infusion over 10-15 min prior to general anaesthesia
Study: NCT06228560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-003
Description: Liquid in vial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-003
Description: Liquid in vial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-003
Description: Liquid in vial

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid in vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Liquid in vial
Study: NCT06186011

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wire-guided surgery
Description: If assigned to the WGS, the marking will be performed by the radiologist on the day prior to the intervention.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radioactive seed localization
Description: If assigned to the RSL, the marking will be performed by the radiologist on the day prior to the intervention. The handling and traceability will be done by the nuclear medicine physician.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative ultrasound localization
Description: If the patient is assigned to the Intraoperative ultrasound localization (IOUS), no further procedures will be necessary until surgery. Subsenquently, the primary surgery will be performed.
Study: NCT06017440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXERCISE
Description: Participants will receive at 08:00 am a calibrated breakfast of 500kcal. They should not perform physical exercise during the day. They will be asked at 11 a.m. to cycle for 30 minutes at 65% of the maximal capacities and their energy expenditure will be measured by indirect calorimetry. At 11 a.m., teenagers will receive a calibrated meal of 800 kcal respecting the nutritional recommendations for this age. Questionnaires on feelings of hunger will be distributed to them at regular intervals. They will also be asked to complete a 10-minute computer exercise to assess their relationship to food before and after lunch (LFPQ. Leeds Food Preference Questionnaire, Liking/ wanting). Finally, from 60 minutes after the midday test meal, teenagers will have access to an ad libitum buffet for one hour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONTROL
Description: Teenagers should not perform any physical activity during the day and they will be asked to stay at 11 a.m., for 30 minutes, resting in a semi-supine position.
Study: NCT04233554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Priorities Care
Description: Patients will participate in a structured conversation in which the facilitator (i.e. social worker) helps patients identify their health goals, measurable, actionable, realistic outcomes (e.g. walk ½ mile daily). Both practice and patient level data will be collected.